BioStock: Saniona has started dosing in the SAN711 trial

Saniona has initiated dosing of the first subjects with SAN711 in a phase I multiple ascending dose biomarker study, aiming to release topline data by the end of the year. The CEO, Thomas Feldthus, see this as a milestone and a crucial step towards the goal of starting a clinical proof-of-concept study in children with absence seizures next year.
– This study with SAN711 in healthy volunteers offers valuable insights into the appropriate dosing for our phase II trial, helping to ensure positive outcomes.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/10/saniona-has-started-dosing-in-the-san711-trial/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/